Yubo International Biotech Limited
YBGJ
$0.0163
-$0.0097-37.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -99.43% | -96.05% | 90.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -99.43% | -96.05% | 90.00% |
| Cost of Revenue | -61.34% | 135.71% | 13.14% | -0.09% | 53.03% |
| Gross Profit | -135.44% | -157.93% | -149.71% | -145.27% | 144.08% |
| SG&A Expenses | 7.33% | 20.32% | 11.83% | 142.05% | 142.13% |
| Depreciation & Amortization | -28.32% | -20.09% | -3.58% | 196.30% | 468.39% |
| Other Operating Expenses | -55.71% | -2.45% | 9.55% | -1.23% | -21.06% |
| Total Operating Expenses | -14.28% | 17.00% | 9.96% | 76.74% | 86.18% |
| Operating Income | -11.36% | -58.41% | -65.61% | -272.65% | -85.06% |
| Income Before Tax | -11.33% | -58.37% | -65.83% | -273.85% | -85.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.33% | -58.37% | -65.83% | -273.85% | -85.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 50.00% | 539.44% | -- | -- | -- |
| Net Income | -8.51% | -46.02% | -48.55% | -248.89% | -72.99% |
| EBIT | -11.36% | -58.41% | -65.61% | -272.65% | -85.06% |
| EBITDA | -19.51% | -75.20% | -78.64% | -286.07% | -62.87% |
| EPS Basic | 68.33% | 60.82% | -335.35% | -857.45% | -489.71% |
| Normalized Basic EPS | 68.62% | 61.80% | -303.17% | -764.52% | -443.18% |
| EPS Diluted | 68.33% | 60.82% | -335.35% | -857.45% | -489.71% |
| Normalized Diluted EPS | 68.62% | 61.80% | -303.17% | -764.52% | -443.18% |
| Average Basic Shares Outstanding | 29.03% | 29.03% | -22.50% | -22.50% | -22.32% |
| Average Diluted Shares Outstanding | 29.03% | 29.03% | -22.50% | -22.50% | -22.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |